1951. Guiding COVID-19 Booster Vaccinations by COVID-19 Quantitative Spike Ig Antibody Titers Regardless of HIV Status, Immunosuppression, and Age

por Hsu, Ricky K, Brunet, Laurence, Fusco, Jennifer S
Publicado 2022

Antioxidant and Anti-Inflammatory Properties of Walnut Constituents: Focus on Personalized Cancer Prevention and the Microbiome

por Fan, Nuoxi, Fusco, Jennifer L., Rosenberg, Daniel W.
Publicado 2023

936. Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions Following Initiation of Common...

por Lackey, Philip, Brunet, Laurence, Fusco, Jennifer, Vannappagari, Vani, Ragone, Leigh, Fusco, Gregory
Publicado 2018

555. Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States

por Lackey, Philip, Schulman, Kathy, Fusco, Jennifer, Arduino, Jean Marie, Prajapati, Girish, Fusco, Gregory
Publicado 2018

2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir

por Hsu, Ricky, Schulman, Kathy, Fusco, Jennifer S, Marie Arduino, Jean, Prajapati, Girish, Fusco, Gregory
Publicado 2019

2483. Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States

por Pierone, Gerald, Schulman, Kathy, Fusco, Jennifer S, Vannappagari, Vani, Aboud, Michael, Ragone, Leigh, Fusco, Gregory
Publicado 2019

Two‐drug antiretroviral regimens: an assessment of virologic response and durability among treatment‐experienced persons living with HIV in the OPERA(®) Observational Database

por Pierone, Gerald, Henegar, Cassidy, Fusco, Jennifer, Vannappagari, Vani, Aboud, Michael, Ragone, Leigh, Fusco, Gregory
Publicado 2019

337. Switching from TDF to TAF: Missed Opportunities for Statin Use in HIV

por Mallon, Patrick, Brunet, Laurence, Fusco, Jennifer S, Prajapati, Girish, Beyer, Andrew P, Wohlfeiler, Michael, Fusco, Gregory
Publicado 2019

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen

por Wohlfeiler, Michael, Schulman, Kathy, Fusco, Jennifer S, Punekar, Yogesh, Mills, Anthony, Priest, Julie, Oglesby, Alan, Fusco, Gregory
Publicado 2019

Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization

por Brunet, Laurence, Mallon, Patrick, Fusco, Jennifer S., Wohlfeiler, Michael B., Prajapati, Girish, Beyer, Andrew, Fusco, Gregory P.
Publicado 2021

1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability

por Pierone, Gerald, Fusco, Jennifer S, Brunet, Laurence, Sension, Michael, Dunbar, Megan, Gruber, Joshua, Dieterich, Douglas, Fusco, Gregory P
Publicado 2023

Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides

por Mallon, Patrick W G, Brunet, Laurence, Fusco, Jennifer S, Prajapati, Girish, Beyer, Andrew, Fusco, Gregory P, Wohlfeiler, Michael B
Publicado 2021

Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens

por Mounzer, Karam, Brunet, Laurence, Fusco, Jennifer S, Mcnicholl, Ian R, Diaz Cuervo, Helena, Sension, Michael, Mccurdy, Lewis, Fusco, Gregory P
Publicado 2022

Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice

por Lackey, Philip, Mills, Anthony, Carpio, Felix, Hsu, Ricky, DeJesus, Edwin, Pierone, Gerald, Henegar, Cassidy, Fusco, Jennifer, Fusco, Gregory, Wohlfeiler, Mike
Publicado 2016

1284. Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens

por Pierone, Gerald, Fusco, Jennifer S, Brunet, Laurence, Vannappagari, Vani, Sarkar, Supriya, Henegar, Cassidy, van Wyk, Jean A, Zolopa, Andrew, Fusco, Gregory P
Publicado 2022

Psychiatric Symptoms in Patients Receiving Dolutegravir

por Fettiplace, Anna, Stainsby, Chris, Winston, Alan, Givens, Naomi, Puccini, Sarah, Vannappagari, Vani, Hsu, Ricky, Fusco, Jennifer, Quercia, Romina, Aboud, Michael, Curtis, Lloyd
Publicado 2017

Antiretroviral therapy and liver disorders in the OPERA(®) cohort

por Wohlfeiler, Michael, Mounzer, Karam, Brunet, Laurence, Fusco, Jennifer, Vannappagari, Vani, Curtis, Lloyd, Payvandi, Nassrin, Aboud, Michael, Hsu, Ricky, Lackey, Philip, Fusco, Gregory
Publicado 2020

Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes

por Hsu, Ricky K., Fusco, Jennifer S., Henegar, Cassidy E., Vannappagari, Vani, Clark, Andrew, Brunet, Laurence, Lackey, Philip C., Pierone, Gerald, Fusco, Gregory P.
Publicado 2023

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA(®) observational database: a cohort study

por Mounzer, Karam, Hsu, Ricky, Fusco, Jennifer S., Brunet, Laurence, Henegar, Cassidy E., Vannappagari, Vani, Stainsby, Chris M., Shaefer, Mark S., Ragone, Leigh, Fusco, Gregory P.
Publicado 2019

341. Risk of Type 2 Diabetes Mellitus after Antiretroviral Therapy Initiation in Individuals Living with HIV in the United States

por Hsu, Ricky, Brunet, Laurence, Fusco, Jennifer S, Mounzer, Karam, Vannappagari, Vani, Henegar, Cassidy, van Wyk, Jean A, Curtis, Lloyd D, Lo, Janet, Fusco, Gregory
Publicado 2019